Positions and Employment:
1991-1992 Intern, Internal Medicine, Brigham and
Women’s Hospital, Harvard Medical School, Boston, MA
1992-1994 Resident in Neurology, Harvard Longwood
Neurology Training Program, Boston, MA
1994-1995 Chief Resident in Neurology, Harvard
Longwood Neurology Training Program, Boston, MA
1995-1997 Clinical Fellow in Dementia and
Behavioral Neurology, Harvard Medical School, Boston, MA
1997-2002 Instructor in Neurology, Harvard Medical School
1997-1999 Clinical Investigator Training Program,
Harvard/MIT Health Sciences and Technology
1997- Associate Neurologist, Brigham
and Women’s Hospital, Massachusetts General Hospital,
2002-2006 Assistant Professor of Neurology, Harvard
2003- Director of Clinical Research, Memory
Disorders Unit, Brigham and Women’s Hospital
Neuroimaging Program, Massachusetts ADRC, Massachusetts General Hospital
2007- Associate Professor of Neurology, Harvard
2008- Director, Center for Alzheimer Research
and Treatment, Brigham and Women's Hospital
Experience and Professional Memberships:
2002-2007 Editorial Board, Alzheimer’s Disease and
2002- Steering Committee, Alzheimer’s
Disease Cooperative Study, National Institute on Aging
2003-2006 Chair, Medical-Scientific Advisory
Committee, Massachusetts Chapter, Alzheimer’s Association
2005- Steering Committee, Data and Publications,
Alzheimer’s Disease Neuroimaging Initiative
Member; NIA-N Study Section; National Institutes on Aging
Alzheimer’s Imaging Consortium, Program Committee, ICAD
Academy of Neurology Research Council
NIA/Alzheimer’s Association Working Group on Preclinical Alzheimer’s disease
1987 Magna Cum Laude, Phi Beta Kappa,
1991 Cum Laude, Honors in Special
Field – Neuroscience, Harvard Medical School
1998 AAN Education and Research Foundation Clinical
Research Training Fellowship
Anniversary in Medicine Award, Harvard Medical School
2003 New Project in
Translational Neuroscience Award, Brigham Institute for the Neurosciences
2003 Paul Beeson Faculty Scholars in Aging
Award, American Federation for Aging Research
2006 Memory Ride Award, Investigator Initiated
Grant, Alzheimer’s Association
2007 Research Award in Geriatric Neurology,
American Academy of Neurology
2010 Simons Lecture Awardee, Alzheimer’s
C. Selected Peer-reviewed Publications (selected from over 70 publications)
RA, Bates JC, Cocchiarella
AJ, Schacter D, Rosen B, Albert M.
Encoding novel face-name associations: A functional MRI study. Human
Brain Mapping 2001;14(2):129-139.
R, Greve D, Dale A, Kiliany
R, Rosen R, Homes J, Rosas HD, Cocchiarella A, Firth P, Lange N, Routledge C,
Albert M. Functional MRI Detection of
pharmacologically induced memory impairment. PNAS 2002; 99(1):455-460.
RA, Bates J, Chua E,
Cocchiarella A, Rentz D, Rosen B, Schacter DL, Albert MS. Functional MRI
studies of associative encoding in elderly controls and mild AD patients. JNNP 2003;74:44-50.
BC, Salat D, Bates J, Atiya M, Killiany R, Greve D, Dale AM, Stern CE, Blacker
D, Albert MS, Sperling RA. MRI measures
of medial temporal lobe function and structure in questionable Alzheimer’s
disease. Annals of Neurology, 2004;
- Dickerson, BC, Salat D, Greve
D, Chua E, Rand-Giovannetti E, Rentz D, Betram L, Mullin K, Tanzi R, Blacker D,
Albert M, Sperling R. Increased
hippocampal activation in mild cognitive impairment compared to normal aging
and AD. Neurology 2005;65:404-411.
E, Chua A, Driscoll A, Schacter D, Albert M, Sperling R. Hippocampus and neocortical activation during
repetitive encoding in older persons. Neurobiology
of Aging 2006; 27(1):173-182.
- Rentz DM, Sardinha L, Huh T, Daffner K,
and Sperling RA. IQ-based Norms for Highly Intelligent
Adults. The Clinical Neuropsychologist 2006; 20(4):637-48.
KA, Calhoun VD, Dickerson B, Atri A, Chua EF, Miller S, DePeau K, Rentz DM,
Selkoe D, Blacker D, Albert MS, Sperling RA. Alterations in memory
networks in mild cognitive impairment and Alzheimer’s disease: An independent component analysis J Neuroscience 2006;
- Chappell, AS, Gonzales, Williams, J, Witte, MM,
Mohs, RC, Sperling, RA. AMPA
potentiator treatment of cognitive deficits in Alzheimer disease. Neurology 2007; 68 1008-1012.
- Diamond EL, Miller S, Dickerson BC, Atri A, DePeau K,
Fenstermacher E, Pihlajamäki M, Celone K,
Salisbury S, Gregas M, Rentz D, Sperling RA. Relationship of fMRI
Activation to Clinical Trial Memory Measures in Alzheimer's Disease. Neurology 2007;69(13):1331-41.
SL, Celone K, DePeau K, Diamond E, Dickerson BC, Rentz D, Pihlajamäki M, Sperling RA. Age-related
memory impairment associated with loss of parietal deactivation but preserved
hippocampal activation. Proceedings of
the National Academy of Sciences 2008;105(6):2181-6. PMCID: PMC2538895.
- Buckner R, Sepulcre
J, Talukdar T, Krienen F, Liu H, Hedden T, Andrews-Hanna J, Sperling R, Johnson K. Cortical Hubs Revealed
by Intrinsic Functional Connectivity: J
Neuroscience 2009; 29(6):1860-73. PMC2750039
- Sperling RA, LaViolette PS, O’Keefe K, et al. Amyloid Deposition is Associated with
Impaired Default Network
Function in Older Persons without Dementia.
Neuron 2009; 63: 178-188. PMC2738994
- O'Brien JL, O'Keefe KM, LaViolette PS, DeLuca AN,
Blacker D, Dickerson BC, Sperling RA.
Longitudinal fMRI in elderly reveals loss of hippocampal activation with
clinical decline. Neurology 2010;74(24):1969-76.
- Becker JA, Hedden T, Carmasin J, Maye J, Rentz D,
Putcha D, Fischl B, Greve D, Marshall GA, Salloway S,
Marks D, Buckner RL, Sperling RA,
Johnson KA. Amyloid-beta Associated Cortical Thinning in Clinically Normal
Elderly. Annals of Neurology, in
press (available on line).
P01AG036694-01 Sperling (PI)
07/15/10- 6/30/15 NIH/NIA
Impact of Amyloid on the Aging Brain
The overall goals of the PPG are to elucidate the biological
significance of amyloid deposition in the aging brain and determine if
cognitively normal older individuals are on the trajectory towards prodromal
Investigator; Administrative and Clinical Core Leader, PI- Project 2
R01-AG027435 and R01-AG027435-S1 Sperling (PI)
– 01/31/12 NIH/NIA
Evolution of memory-related fMRI activation
over the course of MCI and AD
The major goal of this study is to develop functional MRI
as a biomarker for clinical trials and longitudinal studies of disease
progression in MCI and AD. The goal of the supplement is to investigate
relationship of amyloid deposition to memory dysfunction in MCI.
Role: Principal Investigator
P50 AG00513421 Hyman (PI) – Sperling (PL)
4/30/2009 - 3/31/2014 NIH/NIA
Massachusetts Alzheimer's Disease Research Center Neuroimaging Program
and Project 1
The major goal of this project is to capture all ADRC related
neuroimaging in an electronic database and provide support to ADRC related
imaging projects. Project 1 goal is to
study cognitively normal older subjects participating in ADRC cohort with PiB
and MRI imaging to investigate markers of prodromal AD.
Role: Principal Investigator- Project 1; NeuroImaging Program Leader
K24 AG035007 Sperling (PI)
– 9/30/15 NIH/NIA
Mentoring Imaging Research in Early ADThe overall goal of this Career Development Award is to provide
support for mentoring early investigators training in clinical and imaging
research in Alzheimer’s disease.
R01AG034556 (Buckner, PI)
Neural Processes Underlying Cognitive Aging
The major goal of this project is to investigate age-related
changes in fronto-parietal large scale networks
R01 AG037497-01 (K. Johnson, PI)
Characterizing the Evolution of Amyloid Deposition in Normal
The major goal of this project is to investigate the longitudinal
pattern of amyloid accumulation in cognitively normal older subjects
Investigator Foundation Grant Sperling (PI)
- 12/14/11 NIH/NIA
Fidelity Medical Foundation
Imaging and Biomarker Indicators of Prodromal Alzheimer's disease
This pilot project will investigate molecular, structural, and
functional imaging markers and biofluid markers for prodromal AD in cognitively normal older individuals with
evidence of amyloid pathology on PiB-PET.
Role: Principal Investigator
Foundation Grant - Sperling (PI)
– 9/30/13 AHAF
Health Assistance Foundation – Alzheimer’s grant program
vulnerability in amyloid positive elderly
overall goal of this Foundation grant is to determine if older individuals with
high amyloid burden will demonstrate heightened vulnerability to anticholinergic
medication and associated brain dysfunction.
U01-AG024904 Weiner (PI)
/ Sperling (Site PI)
12/01/04 – 11/30/15 NIH
Alzheimer’s Disease Neuroimaging Initiative (ADNI)
The objective of the study is to develop and validate neuroimaging,
neuropsychological measures, and biomarkers for clinical trials of
disease-modifying agents in MCI and AD.
Role: Site Principal Investigator; Steering Committee, Data and
U01AG032438 (Morris PI/Sperling Site PI)
Dominantly Inherited Alzheimer Network
The goal of this cooperative study is to establish an international
network studying autosomal dominant genetic risk for AD, with PiB-PET, MRI, and
Role: Site Principal Investigator, Steering Committee
R01AG029411 Dickerson (PI)
- 06/30/12 NIH/NIA
Medial temporal lobe subregions in aging, MCI and AD:
Structural and functional MRI
The primary goal of this project is to determine whether
MTL-subregion-specific functional changes can be found in PreMCI before
structural changes are detected.
Corporate Sponsored Research Sperling (PI)
09/01/09 – 3/01/11 Bristol-Myers-Squibb
A Multicenter, Randomized, Study of BMS-708163 in the Treatment of
Patients With Prodromal AD.
The major goal of this Phase II trial of a gamma-secretase is to
investigate the effects of lowering amyloid production in prodromal AD. This trial has a PET amyloid imaging
component, and a site-specific functional MRI add to assess the effects of
decreasing amyloid burden on functional connectivity.
Role: Site Principal Investigator
Sponsored Multi-Center Trial Marshall (PI)
- 12/1/11 Elan Pharmaceuticals
Phase II/III study of AAB-001 in patients with mild to
moderate Alzheimer’s Disease.
The major goal of the Phase II study is to examine the
safety, pharmacokinetics, and efficacy of this monoclonal antibody to
beta-amyloid in AD patients.
Role: Site Principal Investigator transitioned to
Investigator Initiated Research Grant Sperling
11/01/06 – 10/31/09 Alzheimer’s
The primary goal of this study is to investigate the relationship of
amyloid deposition to fMRI activation in subjects with mild cognitive impairment.